| editorial | Q871232 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.YJMCC.2014.11.001 |
| P698 | PubMed publication ID | 25450616 |
| P2093 | author name string | Joerg Heineke | |
| Andrea Grund | |||
| P2860 | cites work | Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure | Q21256439 |
| CIB1 is a regulator of pathological cardiac hypertrophy | Q24338983 | ||
| Molecular basis of physiological heart growth: fundamental concepts and new players | Q27006868 | ||
| YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5 | Q28570128 | ||
| Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study | Q29614968 | ||
| Regulation of cardiac hypertrophy by intracellular signalling pathways | Q29615166 | ||
| Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy | Q33974366 | ||
| Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth | Q34544759 | ||
| Cardiac plasticity | Q34764732 | ||
| Cardiac CaM Kinase II genes δ and γ contribute to adverse remodeling but redundantly inhibit calcineurin-induced myocardial hypertrophy | Q35047672 | ||
| Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy | Q35578778 | ||
| Transcription factor GATA4 is activated but not required for insulin-like growth factor 1 (IGF1)-induced cardiac hypertrophy | Q35880015 | ||
| Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy | Q36350066 | ||
| Essential role of stress hormone signaling in cardiomyocytes for the prevention of heart disease. | Q37240638 | ||
| Gene reprogramming in exercise-induced cardiac hypertrophy in swine: A transcriptional genomics approach. | Q38302660 | ||
| Cardiac steroidogenesis and glucocorticoid in the development of cardiac hypertrophy during the progression to heart failure | Q42451860 | ||
| Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome | Q43236751 | ||
| Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. | Q43843213 | ||
| Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload | Q44259257 | ||
| Yin Yang 1 is increased in human heart failure and represses the activity of the human alpha-myosin heavy chain promoter | Q44445863 | ||
| Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding | Q46870302 | ||
| Cardiac-Specific Deletion of Gata4 Reveals Its Requirement for Hypertrophy, Compensation, and Myocyte Viability | Q57396510 | ||
| NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure | Q81269550 | ||
| Akt1 is required for physiological cardiac growth | Q83195147 | ||
| P304 | page(s) | 89-91 | |
| P577 | publication date | 2014-11-13 | |
| P1433 | published in | Journal of Molecular and Cellular Cardiology | Q2061932 |
| P1476 | title | Exercise makes the difference: deconstructing physiological hypertrophy in swine | |
| P478 | volume | 79 |
| Q92118427 | Induction of cardiomyocyte proliferation and angiogenesis protects neonatal mice from pressure overload-associated maladaptation | cites work | P2860 |
Search more.